Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia (MAGNITUDE)

7. august 2020 oppdatert av: Bristol-Myers Squibb

A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Naïve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin

The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA < LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

71

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Australia
      • Herston, Australia, 4029
        • Local Institution
    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • Local Institution
    • Queensland
      • Herston, Queensland, Australia, 4029
        • Local Institution
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Local Institution
    • Victoria
      • Melbourne, Victoria, Australia, 3004
        • Local Institution
  • Den russiske føderasjonen
      • Moscow, Den russiske føderasjonen, 107996
        • Local Institution
      • Saint Petersburg, Den russiske føderasjonen, 191186
        • Local Institution
  • Forente stater
    • California
      • Palo Alto, California, Forente stater, 94304
        • Stanford Boswell Clinic
    • Illinois
      • Chicago, Illinois, Forente stater, 60612
        • Rush University Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Hospital of the University of Pennsylvania
    • Utah
      • Murray, Utah, Forente stater, 84123
        • Clinical Research Centers Of America
  • Frankrike
      • Grenoble, Frankrike, 38043
        • Local Institution
      • Lyon Cedex 04, Frankrike, 69317
        • Local Institution
      • Montpellier Cedex 5, Frankrike, 34295
        • Local Institution
      • Paris Cedex 13, Frankrike, 75651
        • Local Institution
      • Paris Cedex 14, Frankrike, 75679
        • Local Institution
      • Vandoeuvre Les Nancy, Frankrike, 54511
        • Local Institution
  • Italia
      • Firenze, Italia, 50134
        • Local Institution
      • Milan, Italia, 20122
        • Local Institution
      • Roma, Italia, 00185
        • Local Institution
      • Torino, Italia, 10126
        • Local Institution
  • Nederland
      • Amsterdam, Nederland, 1105 AZ
        • Local Institution
      • Nijmegen, Nederland, 6525 GA
        • Local Institution
      • Rotterdam, Nederland, 3015 CE
        • Local Institution
      • Utrecht, Nederland, 3508 GA
        • Local Institution
  • Romania
      • Bucuresti, Romania, 50524
        • Local Institution
      • Constanta, Romania, 900635
        • Local Institution
      • Iasi, Romania, 700506
        • Local Institution
      • Iasi, Romania, 700116
        • Local Institution
  • Spania
      • Barcelona, Spania, 08035
        • Local Institution
      • Madrid, Spania, 28046
        • Local Institution
      • Sevilla, Spania, 41013
        • Local Institution

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Mann

Beskrivelse

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

  • Severe hemophilia (defined as < 1% factor activity level)
  • Infection with the hepatitis C virus (HCV) with underlying hemophilia
  • Males 18 years of age and above
  • Have not been previously treated with an interferon

Exclusion Criteria:

  • Not infected with the hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
  • Chronic liver disease caused by any disease other than chronic HCV infection
  • Presence of Bethesda inhibitor
  • Current evidence of or history of portal hypertension

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Cohort A: Genotype-2,-3 (Lambda/RBV/DCV)

Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 12 weeks

Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 12 weeks

Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks
Legemiddel: Ribavirin
Legemiddel: Daclatasvir
Andre navn:
  • BMS-790052
Biologisk: Pegylated-Interferon-lambda
Andre navn:
  • BMS-914143
  • pegIFNλ
Eksperimentell: Cohort B: Genotype-1b,-4 (Lambda/RBV/DCV)

Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 24 weeks

Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 24 weeks

Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks
Legemiddel: Ribavirin
Legemiddel: Daclatasvir
Andre navn:
  • BMS-790052
Biologisk: Pegylated-Interferon-lambda
Andre navn:
  • BMS-914143
  • pegIFNλ

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants Who Achieved Sustained Virologic Response (SVR12) at Follow-Up Week 12
Tidsramme: Follow-up Week 12
SVR12 was defined as HCV ribonucleic acid (RNA) less than the lower limit of quantitation, target detected or target not detected at follow-up Week 12.
Follow-up Week 12

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants With Rapid Virologic Response (RVR)
Tidsramme: Treatment Week 4
RVR was defined as HCV RNA less than the lower limit of quantitation, target not detected at Week 4.
Treatment Week 4
Percentage of Participants With Complete Early Virologic Response (cEVR)
Tidsramme: Treatment Week 12
cEVR was defined as HCV RNA less than the lower limit of quantitation, target not detected at Week 12.
Treatment Week 12
Percentage of Participants With End of the Treatment Response (EOTR)
Tidsramme: End of the treatment (Week 12 for Cohort A, Week 24 for Cohort B)
EOTR was defined as HCV RNA less than the lower limit of quantitation, target not detected at end of treatment.
End of the treatment (Week 12 for Cohort A, Week 24 for Cohort B)
Percentage of Participants With Sustained Virologic Response at Follow-Up Week 24 (SVR24)
Tidsramme: Follow-up Week 24
SVR24 was defined as HCV RNA less than the lower limit of quantitation, target detected or target not detected at follow-up week 24.
Follow-up Week 24
Percentage of Participants With Treatment-Emergent Cytopenic Abnormalities On-Treatment
Tidsramme: After day 1 to end of treatment (Up to 85 Days for Cohort A, Up to 168 Days for Cohort B)
Cytopenic abnormalities were defined as anemia: Hemoglobin (Hb) <10 g/dL, and/or neutropenia: absolute neutrophils and bands (ANC) <750 mm^3, and/or thrombocytopenia: platelets <50,000 mm^3.
After day 1 to end of treatment (Up to 85 Days for Cohort A, Up to 168 Days for Cohort B)
Percentage of Participants With Flu-Like Symptoms and Musculoskeletal Symptoms On-Treatment
Tidsramme: After day 1 to end of treatment (Up to 85 Days for Cohort A, Up to 168 Days for Cohort B)
Flu-like symptoms were defined as pyrexia or chills or pain. Musculoskeletal symptoms were defined as arthralgia or myalgia or back pain.
After day 1 to end of treatment (Up to 85 Days for Cohort A, Up to 168 Days for Cohort B)
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Dose Reductions, And Death
Tidsramme: From Day 1 to end of follow-up (maximum of 60 weeks for Cohort A and 72 weeks for Cohort B)
AE=any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Treatment-related SAE=possibly, probably, or certainly related to study drug.
From Day 1 to end of follow-up (maximum of 60 weeks for Cohort A and 72 weeks for Cohort B)
Number of Participants With Treatment Emergent Grade 3 to 4 Laboratory Abnormalities
Tidsramme: After day 1 to to end of treatment (Up to 85 Days for Cohort A, Up to 168 Days for Cohort B)
Laboratory abnormalities were determined and graded using the Division of acquired immunodeficiency syndrome (AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, version 1.0. International Normalized Ratio (INR): >2.0*Upper limit of normal (ULN); Alanine aminotransferase (ALT) : >5*ULN; Aspartate aminotransferase (AST): >5*ULN; Prothrombin Time (PT): >1.50*ULN; Bilirubin (Total): >2.5*ULN; Triglycerides (fasting): >750 mg/dL.
After day 1 to to end of treatment (Up to 85 Days for Cohort A, Up to 168 Days for Cohort B)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Bristol-Myers Squibb

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

31. mars 2013

Primær fullføring (Faktiske)

31. januar 2015

Studiet fullført (Faktiske)

31. januar 2015

Datoer for studieregistrering

Først innsendt

3. desember 2012

Først innsendt som oppfylte QC-kriteriene

3. desember 2012

Først lagt ut (Anslag)

5. desember 2012

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

11. august 2020

Siste oppdatering sendt inn som oppfylte QC-kriteriene

7. august 2020

Sist bekreftet

1. august 2020

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • AI452-030
  • 2012-003463-22 (EudraCT-nummer)

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere